|drug2558||Placebo pMDI Wiki||1.00|
|drug1203||Ensifentrine Dose 1 Wiki||1.00|
|drug3633||Vitamin D3 Wiki||0.41|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
There is evidence that a specific plant polyphenol (a commercially available supplement) might help fight coronavirus as well as help protect the body from the effects of disease (COVID-19) caused by the infection. In this proof-of-concept pilot study we will compare the effects of a specific plant polyphenol to placebo to assess the safety of the polyphenol and explore effectiveness.
Description: Proportion of study participants admitted to the hospital within 21 days of randomizationMeasure: Hospitalization rates for COVID-19 Time: 21 days from study randomization
Description: Proportion of study participants admitted within 21 who subsequently get admitted to the ICUMeasure: ICU Admission Rates Time: 21 days from randomization
Description: Proportion of study participants who get admitted with 21 day of randomization who receiving invasive ventilation.Measure: Invasive Ventilation Rates Time: 21 days from randomization
Description: Diarrhea, nausea, abdominal crampingMeasure: Adverse events Time: 60 days from randomization
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports